Patent ID: 7887840
Filing Date: 2011-02-15
Classification: A61K,A61P,B82Y

Abstract:
1. A composition comprising: (a) a drug in a solubility-improved form which provides, when administered to a use environment, at least one of a dissolved drug concentration in said use environment that exceeds an equilibrium concentration of a lowest solubility form of said drug in said use environment and a dissolution rate that exceeds a dissolution rate of said lowest solubility form of said drug in said use environment; and (b) a concentration-enhancing polymer selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, cellulose acetate phthalate, hydroxypropyl methyl cellulose phthalate, and cellulose acetate trimellitate wherein said concentration-enhancing polymer is present in a sufficient amount so that said composition provides, after introduction to said use environment, a maximum concentration of said drug in said use environment that is at least 1.25-fold a maximum concentration of said drug provided by a control composition, wherein said control composition is an equivalent quantity of said drug in said solubility-improved form alone; wherein said solubility-improved form is selected from the group consisting of drug in nanoparticulate form, absorbed drug, drug in a nanosuspension, a supercooled melt of drug, cyclodextrin/drug form, gelatin form, softgel form, and three phase form; and wherein said drug in said nanoparticulate form comprises a surface modifier adsorbed on said surface of said drug, and said concentration enhancing polymer is separate from said surface modifier.